Jan 31 (Reuters) - Medical equipment maker Revvity (RVTY.N), opens new tab forecast full-year profit and revenue for 2025 below Wall Street estimates on Friday, as it expects soft demand for its ...

Revvity expects 2025 revenue to be in the range of $2.80 billion to $2.85 billion, compared with estimates of $2.87 billion. The company, however, beat fourth-quarter profit and revenue estimates ...

Revvity has acquired companies in sectors with high-growth potential, such as cell and gene therapies, and precision medicine, among other sectors. The company has strengthened its debt position ...

Life sciences company Revvity (NYSE:RVTY) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.8% year on year to $729.4 million. On the other hand, the company’s full-year ...

As labs go back to conducting non-covid-19 work and tests, Revvity products may remain the equipment and consumables of choice in the post-covid-19 environment for those labs. Also, as Revvity ...

WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in March 2025: 46th Annual Raymond James Institutional Investor ...

(RTTNews) - Revvity, Inc. (RVTY) announced a profit for its fourth quarter that increased from last year and beat the Street estimates. The company's earnings totaled $94.65 million, or $0.78 per ...

Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will be available for at least 30 days. At Revvity, “impossible” is inspiration ...

Revvity (RVTY) came out with quarterly earnings of $1.42 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.25 per share a year ago. These figures ...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Revvity, Inc. (RVTY) on Friday reported fourth-quarter net income of $94.6 million. The Waltham, Massachusetts-based company said it had net income ...